How to Get Jardiance in Maryland

What Is Jardiance and Why Maryland Clinicians Prescribe It

Empagliflozin, sold as Jardiance, is an FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor taken once daily by mouth. The FDA has approved it for three distinct indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and reduction of hospitalization for heart failure and cardiovascular death in adults with heart failure with reduced ejection fraction. A fourth indication, slowing eGFR decline in adults with CKD at risk of progression, was added in 2023. [1]

The cardiovascular mortality data drove widespread adoption. In EMPA-REG OUTCOME (N=7,020), empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) over a median follow-up of 3.1 years. [2] Cardiovascular death alone fell by 38%. [2]

For heart failure, EMPEROR-Reduced (N=3,730) showed that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for worsening heart failure by 25% versus placebo (HR 0.75; 95% CI 0.65 to 0.86; P<0.001). [3] The benefit appeared within the first 12 days of treatment. [3]

Kidney protection data come from EMPA-KIDNEY (N=6,609), which demonstrated that empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo (HR 0.72; 95% CI 0.64 to 0.82; P<0.001). [4] The trial enrolled patients with eGFR as low as 20 mL/min/1.73 m2, expanding the population who may benefit. [4]

The American Diabetes Association Standards of Care (2024) recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred add-on agents for adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD. [5]

Who Can Prescribe Jardiance in Maryland

Any licensed Maryland prescriber with DEA and state prescribing authority may write a Jardiance prescription. Maryland grants nurse practitioners full practice authority without a physician supervisory agreement, meaning an NP can initiate, adjust, and manage empagliflozin therapy independently. [6] Physician assistants in Maryland may prescribe under a delegation agreement with a supervising physician. MDs and DOs face no additional restrictions.

Telehealth prescribers must hold an active Maryland license or qualify under Maryland's reciprocal licensure provisions. Maryland is a member of the Interstate Medical Licensure Compact (IMLC), so out-of-state physicians holding a compact license valid for Maryland may prescribe via telehealth without a separate Maryland license application. [7]

Maryland law does not require an in-person visit before a new prescription is issued via telehealth for non-controlled substances. Empagliflozin is not a controlled substance, so a telehealth consultation alone satisfies the prescribing requirement. The prescriber must conduct a synchronous (live audio-video) visit or, in some cases, an asynchronous review if the platform documents clinical sufficiency. [7]

Labs Required Before Starting Jardiance in Maryland

Baseline laboratory work protects patient safety and is required by virtually every insurer for prior authorization. The minimum panel before empagliflozin is appropriate includes:

Kidney function. A basic or comprehensive metabolic panel provides serum creatinine and eGFR. Empagliflozin is not recommended as a glucose-lowering agent when eGFR falls below 30 mL/min/1.73 m2, though the FDA label allows continuation for cardiorenal protection at lower eGFR ranges. [1] The 2024 ADA Standards specify that SGLT2 inhibitors should generally not be initiated for glycemic control when eGFR is <30 mL/min/1.73 m2. [5]

Glycemic status. HbA1c confirms the diabetes diagnosis and documents baseline control. Most Maryland insurers require a documented HbA1c of 7.0% or higher for prior authorization of the diabetes indication. [8]

Urine albumin. A spot urine albumin-to-creatinine ratio (UACR) is used to stage CKD and is required for PA of the CKD indication. EMPA-KIDNEY enrolled patients with UACR 200 mg/g or higher (or eGFR 20 to 44 regardless of UACR), so those thresholds guide clinical decisions. [4]

Liver function. A hepatic panel is standard before initiating any chronic medication, though empagliflozin does not carry a liver-specific boxed warning. [1]

Genital hygiene history. Patients with recurrent urinary tract infections or a history of genital mycotic infections face higher rates of these side effects on SGLT2 inhibitors. A brief history review, not a lab test, informs counseling. The prescriber should document this discussion in the chart. [9]

Results from labs drawn within the past 90 days are generally accepted by Maryland insurers for prior authorization purposes, though individual plan policies vary. [8]

How to Get a Jardiance Prescription in Maryland Step by Step

The process has four stages: consult, labs, prescription, and pharmacy.

Stage 1: Schedule a consult. Book a telehealth visit with a Maryland-licensed prescriber through a platform such as HealthRX or an in-person appointment with a primary care physician, endocrinologist, or cardiologist. Bring your list of current medications, any recent lab results, and your insurance card. [7]

Stage 2: Complete labs. If you have no recent labs, the prescriber will order a same-day lab requisition through Quest Diagnostics, LabCorp, or a Maryland hospital outpatient lab. Both Quest and LabCorp have more than 40 patient service centers in Maryland, including locations in Baltimore, Rockville, Silver Spring, Bethesda, Annapolis, and Frederick. Results typically return within 24 hours for a basic metabolic panel. [10]

Stage 3: Receive the prescription. Once labs confirm safety (adequate eGFR, documented diabetes or CVD/HF/CKD indication), the prescriber sends an electronic prescription to your chosen pharmacy. For patients on Maryland Medicaid or a commercial plan requiring prior authorization, the prescriber's office submits PA paperwork simultaneously. PA decisions on Maryland Medicaid typically come back within 72 hours for standard review or 24 hours for expedited review. [8]

Stage 4: Fill at pharmacy. Take the prescription to a retail pharmacy, a mail-order pharmacy, or a Maryland-licensed 503A compounding pharmacy. Retail options include CVS (114 locations in Maryland), Walgreens (78 locations), Rite Aid, and independent pharmacies. Mail-order options through major PBMs reduce cost for 90-day supplies. [11]

Maryland Medicaid and Commercial Insurance Coverage

Maryland Medicaid (HealthChoice) covers brand-name Jardiance on its preferred drug list with prior authorization. The required PA documentation typically includes the member's HbA1c, current antidiabetic regimen, eGFR, UACR, and the specific FDA-approved indication being treated. [8]

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit should be used." [5] Quoting this guideline directly in the PA letter strengthens the medical necessity argument.

For commercial insurance, Boehringer Ingelheim offers the Jardiance Savings Card, which reduces out-of-pocket costs to as low as $10 per 30-day fill for eligible commercially insured patients. [12] Patients on Medicare Part D cannot use manufacturer coupons but may qualify for Low-Income Subsidy (LIS) programs or the Medicare Inflation Reduction Act $2,000 annual out-of-pocket cap effective 2025. [13]

The average wholesale price (AWP) for Jardiance 10 mg (30 tablets) is approximately $622 without insurance. GoodRx and similar platforms list Maryland retail prices between $540 and $590 at major chains. [11] A 90-day mail-order supply through a PBM preferred pharmacy may reduce this cost by 10 to 15% for commercially insured patients. [11]

Telehealth Providers in Maryland Prescribing Jardiance

Maryland permits synchronous telehealth prescribing of empagliflozin without a prior in-person visit. The Maryland Board of Physicians defines telehealth as the use of interactive audio-video technology enabling a provider to examine and treat a patient at a distant site. [7] The standard of care must equal that of an in-person visit.

Telehealth platforms operating in Maryland and offering endocrinology, cardiology, or primary care services include HealthRX, Teladoc Health, MDLive, and Amazon Clinic. When choosing a platform, confirm that the prescribing clinician holds a Maryland license and that the platform uses asynchronous intake forms followed by synchronous review, so the visit meets Maryland's prescribing standards. [7]

The Maryland Health Benefit Exchange facilitates insurance enrollment that covers telehealth visits under the same cost-sharing rules as in-person visits, per the Maryland Telehealth Parity Law. [7] This means a patient's Jardiance consult costs the same copay as an in-person office visit for covered plans.

The HealthRX Maryland Access Framework for empagliflozin identifies three patient categories:

1. Commercial insurance, no prior CVD/HF/CKD. Telehealth consult plus HbA1c and BMP. Standard PA with ADA guideline citation. Expected time to fill: 3 to 5 business days.
2. Maryland Medicaid HealthChoice. Telehealth consult, full lab panel, expedited PA request citing EMPA-REG OUTCOME and ADA 2024. Expected time to fill: 2 to 4 business days.
3. Uninsured or Medicare Part D gap. Telehealth consult, lab panel, cash-pay prescription to 503A pharmacy or GoodRx pricing at retail chain. Expected time to fill: 1 to 2 business days (no PA required).

503A Compounding Pharmacies in Maryland

Maryland-licensed 503A pharmacies may compound empagliflozin for individual patients when a valid prescription exists and the prescriber documents a clinical rationale for compounding over the commercially available product. [14] 503A pharmacies prepare medications on a patient-specific basis under USP 795 (non-sterile) standards. [14]

The FDA does not recognize empagliflozin as a commercially available shortage drug, so 503A compounding is permissible only when the prescriber documents patient-specific reasons such as allergy to inactive ingredients in the commercial tablet, need for an alternative dose form (liquid suspension for dysphagia), or a documented cost barrier with supporting documentation. [14]

Maryland's Board of Pharmacy maintains a list of licensed compounding pharmacies on its website. Patients should verify that the compounding pharmacy holds an active Maryland Board of Pharmacy license before accepting a compounded empagliflozin product. [15]

Transferring an Existing Jardiance Prescription to Maryland

Patients relocating to Maryland who already have a Jardiance prescription from another state can transfer refills to a Maryland retail pharmacy within the same chain network. CVS, Walgreens, and Rite Aid allow same-network transfers by phone or through their mobile apps. [11]

A transferred prescription remains valid for the number of refills originally authorized, provided the prescribing physician is still licensed in their original state and the prescription was written within the past 12 months (Maryland's standard Rx validity window for non-controlled substances). [16]

If the original prescriber is not licensed in Maryland and the patient has exhausted refills, a new Maryland prescriber must issue a fresh prescription. A telehealth consult handles this in one business day for patients with recent labs on file. The new prescriber will request records from the previous provider or accept a medication history printout from the pharmacy as documentation of the prior regimen. [7]

How Long Until You Receive Jardiance in Maryland

Time to first dose depends on insurance and whether prior authorization is required:

No PA required (uninsured, certain commercial plans). Same-day or next-day fill at a retail pharmacy after the telehealth consult. Mail-order typically delivers within 3 to 5 business days. [11]

Commercial insurance PA. Standard PA review takes 2 to 3 business days. Urgent PA (for patients with acute decompensated heart failure or rapidly declining eGFR) may be processed in 24 hours if the prescriber marks the request urgent with clinical documentation. [8]

Maryland Medicaid PA. Maryland Medicaid mandates a 72-hour decision on standard PA requests and a 24-hour decision on expedited requests. [8] If PA is denied, the prescriber may request a peer-to-peer review within 10 calendar days, or the patient may file an appeal. The ADA 2024 guideline recommendation and EMPA-REG OUTCOME cardiovascular mortality data are the strongest clinical arguments in an appeal. [2] [5]

503A compounding. A compounded supply typically ships within 5 to 7 business days after the pharmacy receives the prescription and any required documentation. [14]

Side Effects and Monitoring After Starting Jardiance in Maryland

SGLT2 inhibitors carry a class-level boxed warning for lower-limb amputation risk (based on canagliflozin data), though the absolute risk with empagliflozin was not statistically elevated in EMPA-REG OUTCOME. [2] The FDA label for empagliflozin does not include an individual boxed warning for amputation. [1]

Common adverse effects include genital mycotic infections (occurring in roughly 10% of women and 4% of men in clinical trials) [9], urinary tract infections, and volume depletion, particularly in older adults or those on loop diuretics. [1]

Euglycemic diabetic ketoacidosis (DKA) is a rare but serious risk. The FDA issued a safety communication on SGLT2 inhibitor-associated DKA in 2015. [17] Patients should hold empagliflozin at least 3 days before elective surgery and any procedure requiring prolonged fasting. [1]

Monitoring after initiation should include:

• Repeat BMP or CMP at 4 to 6 weeks to assess eGFR response. A transient 10 to 15% eGFR dip after starting empagliflozin is expected and does not require discontinuation. [4]
• HbA1c at 3 months to assess glycemic response. [5]
• Blood pressure check at follow-up, as empagliflozin produces a mean systolic BP reduction of approximately 3 to 5 mmHg. [2]
• UACR at 6 months for patients with CKD indication to document albuminuria response. [4]

The 2023 KDIGO CKD Guidelines recommend SGLT2 inhibitors for adults with type 2 diabetes and CKD with eGFR 20 mL/min/1.73 m2 or higher when additional kidney or cardiovascular protection is needed. [18]

Cost-Saving Strategies for Maryland Patients

Brand-name Jardiance has no FDA-approved generic equivalent as of July 2025. The primary cost tools available to Maryland patients are:

Manufacturer savings card. Boehringer Ingelheim's Jardiance Savings Card brings the cost to as low as $10 per fill for commercially insured patients who are not on federal programs. [12] The card is available at jardiance.com and can be used at any participating Maryland pharmacy.

340B program. Maryland community health centers and safety-net hospitals that participate in the federal 340B Drug Pricing Program can dispense Jardiance at significantly reduced cost to qualifying low-income patients. The Health Resources and Services Administration (HRSA) maintains a searchable 340B covered entity database. [19]

Patient assistance programs. Boehringer Ingelheim's Patient Assistance Program provides free Jardiance to uninsured patients meeting income thresholds (generally at or below 400% of the federal poverty level). Applications are submitted through the manufacturer's website or through a Maryland social worker. [12]

GoodRx and discount cards. Maryland retail pharmacies honor GoodRx coupons, bringing the cash price of Jardiance 10 mg (30 tablets) to approximately $540 to $590 depending on the specific pharmacy. [11] Independent pharmacies in Baltimore and Montgomery County sometimes offer lower cash prices than chain pharmacies.

Mail-order 90-day supply. Most commercial PBMs charge a lower copay for a 90-day mail-order supply compared to three separate 30-day fills. Confirm with your plan's member services line. [11]